EHA26: AvenCell’s AVC-201-01 switchable allogeneic CAR T offers early validation in AML

Tuesday, June 16, 2026GlobalData HealthcareView original

AvenCell Therapeutics presented updated results for its CAR-T cell blood cancer therapy at EHA 2026.

Read the full article on the original site.